Cambium Bio Raises A$1.0 Million via Placement
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The placement involves the issuance of new fully-paid ordinary shares at a premium to the company's recent closing share price, reflecting confidence in its ongoing projects. This announcement was authorized by the Board of Directors of Cambium Bio Limited.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Cambium Bio
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
- Half Year Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Secures A$2.4 Million Strategic Investment
- Cambium Bio Signs Strategic MoU with Benta SAS
Later from Cambium Bio
- Updated Securities Trading Policy
- Change in Company Secretary and Communication Person
- FY26 Appendix 4G and Corporate Governance Statement
- FY26 Appendix 4E and Annual Report
- Proposed issue of securities - CMB
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio